BLT Stock Overview
Develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BLIS Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.018 |
| 52 Week High | NZ$0.022 |
| 52 Week Low | NZ$0.011 |
| Beta | 0.42 |
| 11 Month Change | 38.46% |
| 3 Month Change | -10.00% |
| 1 Year Change | -5.26% |
| 33 Year Change | -65.38% |
| 5 Year Change | -58.14% |
| Change since IPO | -98.18% |
Recent News & Updates
Recent updates
BLIS Technologies (NZSE:BLT) Is In A Strong Position To Grow Its Business
Dec 05
Calculating The Intrinsic Value Of BLIS Technologies Limited (NZSE:BLT)
Mar 08BLIS Technologies Limited (NZSE:BLT) Insiders Have Been Selling
Feb 09
BLIS Technologies Limited (NZSE:BLT) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Jan 21I Ran A Stock Scan For Earnings Growth And BLIS Technologies (NZSE:BLT) Passed With Ease
Jan 03Should You Use BLIS Technologies's (NZSE:BLT) Statutory Earnings To Analyse It?
Dec 15Introducing BLIS Technologies (NZSE:BLT), The Stock That Soared 371% In The Last Three Years
Nov 28Shareholder Returns
| BLT | NZ Pharmaceuticals | NZ Market | |
|---|---|---|---|
| 7D | -5.3% | -11.4% | 0.1% |
| 1Y | -5.3% | 34.7% | 9.6% |
Return vs Industry: BLT underperformed the NZ Pharmaceuticals industry which returned 34.7% over the past year.
Return vs Market: BLT underperformed the NZ Market which returned 9.6% over the past year.
Price Volatility
| BLT volatility | |
|---|---|
| BLT Average Weekly Movement | 15.8% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in NZ Market | 9.3% |
| 10% least volatile stocks in NZ Market | 3.0% |
Stable Share Price: BLT's share price has been volatile over the past 3 months compared to the NZ market.
Volatility Over Time: BLT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of NZ stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 39 | Scott Johnson | www.blis.co.nz |
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity, and radiance. It has operations in New Zealand, Asia Pacific, Europe, the Middle East, Africa, and North America.
BLIS Technologies Limited Fundamentals Summary
| BLT fundamental statistics | |
|---|---|
| Market cap | NZ$23.03m |
| Earnings (TTM) | NZ$646.00k |
| Revenue (TTM) | NZ$11.57m |
35.6x
P/E Ratio2.0x
P/S RatioIs BLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLT income statement (TTM) | |
|---|---|
| Revenue | NZ$11.57m |
| Cost of Revenue | NZ$2.25m |
| Gross Profit | NZ$9.32m |
| Other Expenses | NZ$8.67m |
| Earnings | NZ$646.00k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.00051 |
| Gross Margin | 80.55% |
| Net Profit Margin | 5.58% |
| Debt/Equity Ratio | 0% |
How did BLT perform over the long term?
See historical performance and comparison